Capricor Therapeutics (NASDAQ:CAPR) Coverage Initiated by Analysts at Roth Capital

Roth Capital assumed coverage on shares of Capricor Therapeutics (NASDAQ:CAPR) in a research note released on Tuesday, MarketBeat.com reports. The brokerage issued a buy rating and a $31.00 target price on the biotechnology company’s stock.

Several other equities research analysts have also recently issued reports on the stock. HC Wainwright reissued a “buy” rating and issued a $77.00 price objective on shares of Capricor Therapeutics in a research report on Monday, March 17th. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $30.00 price target on shares of Capricor Therapeutics in a research note on Wednesday, May 14th. Six analysts have rated the stock with a buy rating, According to data from MarketBeat, the company has an average rating of “Buy” and an average price target of $35.50.

Capricor Therapeutics Stock Up 6.2%

Shares of Capricor Therapeutics stock opened at $11.01 on Tuesday. The stock’s fifty day moving average is $10.61 and its two-hundred day moving average is $13.59. Capricor Therapeutics has a 52 week low of $3.52 and a 52 week high of $23.40. The company has a market capitalization of $502.90 million, a PE ratio of -10.39 and a beta of 0.85.

Capricor Therapeutics (NASDAQ:CAPR) last issued its earnings results on Tuesday, May 13th. The biotechnology company reported ($0.53) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.33) by ($0.20). The company had revenue of $2.73 million for the quarter, compared to analysts’ expectations of $3.16 million. Capricor Therapeutics had a negative net margin of 146.86% and a negative return on equity of 112.95%. During the same period in the prior year, the firm posted ($0.31) earnings per share. As a group, research analysts anticipate that Capricor Therapeutics will post -1.21 earnings per share for the current year.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently added to or reduced their stakes in CAPR. Summit Investment Advisors Inc. lifted its position in shares of Capricor Therapeutics by 54.1% in the 4th quarter. Summit Investment Advisors Inc. now owns 3,832 shares of the biotechnology company’s stock worth $53,000 after purchasing an additional 1,345 shares during the period. Krilogy Financial LLC raised its stake in Capricor Therapeutics by 9.6% in the first quarter. Krilogy Financial LLC now owns 22,800 shares of the biotechnology company’s stock worth $216,000 after buying an additional 2,000 shares in the last quarter. Charles Schwab Investment Management Inc. lifted its holdings in Capricor Therapeutics by 2.1% during the first quarter. Charles Schwab Investment Management Inc. now owns 113,650 shares of the biotechnology company’s stock worth $1,079,000 after buying an additional 2,314 shares during the period. The Manufacturers Life Insurance Company boosted its position in Capricor Therapeutics by 22.4% during the 4th quarter. The Manufacturers Life Insurance Company now owns 12,919 shares of the biotechnology company’s stock valued at $178,000 after acquiring an additional 2,361 shares in the last quarter. Finally, Invesco Ltd. increased its holdings in shares of Capricor Therapeutics by 20.5% in the 4th quarter. Invesco Ltd. now owns 14,678 shares of the biotechnology company’s stock valued at $203,000 after acquiring an additional 2,500 shares during the period. 21.68% of the stock is currently owned by institutional investors.

About Capricor Therapeutics

Capricor Therapeutics, Inc (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor’s lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.